Blog
RSS FeedPosted by Michael Wonder on 16 Apr 2026
ICER releases white paper on accelerated approval pathway for prescription drugs
16 April 2026 - The ICER, in collaboration with Verdant Research, has published a new white paper today that examines the ...
Posted by Michael Wonder on 16 Apr 2026
Savara announces the US FDA has extended the review period for the molgramostim inhalation solution biologics license application in autoimmune pulmonary alveolar proteinosis
15 April 2026 - Savara today announced that the FDA has extended the review period for the molgramostim BLA in ...
Posted by Michael Wonder on 16 Apr 2026
Health Canada approves Cysklar (cysteamine ophthalmic solution) 0.44% for treatment of corneal crystals in people with cystinosis
15 April 2026 - Leadiant Biosciences today announced that Health Canada has approved Cysklar (cysteamine ophthalmic solution) 0.44%, a topical eye ...
Posted by Michael Wonder on 16 Apr 2026
The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder cancer to pay less for new and expanded PBS medicines
16 April 2026 - The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder ...
Posted by Michael Wonder on 16 Apr 2026
Health Canada approves neffy - the first needle free epinephrine spray for anaphylaxis
15 April 2026 - ALK-Abello today announced that Health Canada has approved neffy 2 mg for the emergency treatment of ...
Posted by Michael Wonder on 16 Apr 2026
Opna Bio announces fast track designation granted to OPN-6602 for the treatment of multiple myeloma
15 April 2026 - Opna Bio today announced that the US FDA has granted fast track designation to OPN-6602, a dual ...
Posted by Michael Wonder on 16 Apr 2026
Arbutus receives US FDA fast track designation for imdusiran for the treatment of chronic hepatitis B
15 April 2026 - Arbutus Biopharma today announced that the US FDA has granted fast track designation for imdusiran for the ...
Posted by Michael Wonder on 15 Apr 2026
Partner Therapeutics announces submission of supplemental biologics license application to FDA for Bizengri (zenocutuzumab-zbco) in NRG1 fusion positive cholangiocarcinoma
14 April 2026 - Partner Therapeutics announces the submission of a supplemental biologics license application to the US FDA for Bizengri ...
Posted by Michael Wonder on 15 Apr 2026
Aligos Therapeutics announces first interim analysis results from the Phase 2 B-SUPREME study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection and grant of FDA fast track designation
14 April 2026 - Aligos Therapeutics today announced the first interim analysis results of the Phase 2 B-SUPREME study of pevifoscorvir ...
Posted by Michael Wonder on 15 Apr 2026
Praxis Precision Medicines announces FDA acceptance of new drug application for ulixacaltamide hydrochloride in patients with essential tremor
14 April 2026 - - Praxis Precision Medicines today announced that the US FDA has accepted for review its new drug ...
Posted by Michael Wonder on 15 Apr 2026
My brother can’t access a just approved breakthrough drug for his rare disease
14 April 2026 - A new therapy for Hunter syndrome highlights the inequities of age-based approvals. ...
Posted by Michael Wonder on 14 Apr 2026
Teenager with debilitating illness fights for affordable life-changing medication
13 April 2026 - Brave South Australian teenager Mia McCarthy feels she’s one of “the lucky ones”, despite living with ...
Posted by Michael Wonder on 14 Apr 2026
Cancer patient’s plea for Pfizer to rejoin PBS talks on breakthrough drug
14 April 2026 - Pharmaceutical giant Pfizer has abandoned negotiations to have a breakthrough cancer drug listed on the Pharmaceutical ...
Posted by Michael Wonder on 14 Apr 2026
Travere Therapeutics announces full FDA approval of Filspari (sparsentan), the first and only approved medicine for FSGS
13 April 2026 - Travere Therapeutics today announced that the US FDA has approved Filspari (sparsentan) to reduce proteinuria in adult ...
Posted by Michael Wonder on 14 Apr 2026
Saphnelo subcutaneous approved in Canada for the treatment of systemic lupus erythematosus
13 April 2026 - Health Canada has granted a notice of compliance for Saphnelo (anifrolumab injection) for subcutaneous self-administration via a ...